Search results
Gilead’s seladelpar shows promise in primary biliary cholangitis trial
Clinical Trials Arena via Yahoo Finance· 51 minutes agoGilead Sciences has reported promising two-year interim data from the ongoing Phase III ASSURE study...
Gilead progresses subject enrolment in HIV prevention trials
Clinical Trials Arena via Yahoo Finance· 1 day agoGilead Sciences has announced the progression of subject enrolment in two Phase II collaborative...
Gilead Sciences: Preserving Fertility in the Face of a Cancer Diagnosis
Morningstar· 20 hours agoAccording to the National Breast Cancer Foundation, about 9% of women diagnosed with breast cancer in the United States are younger than 45 years old. While surgery and radiation rarely affect ...
... and Consistent Long-Term Efficacy and Safety Profile in Primary Biliary Cholangitis - Gilead ...
Benzinga· 1 day agoGilead Sciences, Inc. GILD, following the recent acquisition of CymaBay Therapeutics, Inc., today announced two-year interim results from the ongoing ASSURE ...
Paulson Wealth Management Inc. Grows Stake in Gilead Sciences, Inc. (NASDAQ:GILD)
ETF DAILY NEWS· 3 days agoPaulson Wealth Management Inc. grew its position in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 5.3% in the 4th quarter, according to its most ...
The Zacks Analyst Blog Highlights NextEra Energy, BP, Gilead Sciences, Hamilton Beach and FONAR
Zacks via Yahoo Finance· 2 days agoStocks recently featured in the blog include: NextEra Energy, Inc. NEE, BP p.l.c. BP, Gilead ...
... Is Arcus Biosciences Stock Trading Higher Today? - Arcus Biosciences (NYSE:RCUS), Gilead ...
Benzinga· 3 days agoGilead Sciences and Arcus Biosciences report sustained efficacy and safety in the Phase 2 EDGE-Gastric study for upper GI cancers, showing improved progression-free ...
Hedge Funds are Bullish on This Gene Therapy Stock
Insider Monkey via Yahoo Finance· 3 days agoWe recently compiled a list of the 9 Best Gene Therapy Stocks to Buy Now and in this article, we discuss Gilead Sciences, Inc. (NASDAQ:GILD), which is...
Vir pressures Gilead with hepatitis D cocktail showing early efficacy in phase 2
FierceBiotech· 21 hours agoVir Biotechnology's hepatitis D combination therapy has shown early efficacy in results from a phase...
Gilead’s Phase III urothelial cancer trial fails to meet primary endpoint
Clinical Trials Arena via Yahoo Finance· 6 days agoGilead Sciences has reported that its Phase III TROPiCS-04 clinical trial of Trodelvy in patients...